6622 — Zhaoke Ophthalmology Share News
0.000.00%
- HK$1.19bn
- HK$662.62m
- CNY31.97m
Brief: Zhaoke Ophthalmology Enters 3 Distribution Agreements With Interpharma
Brief: Zhaoke Ophthalmology Posts Loss For Year RMB237.5 Mln
Brief: Zhaoke Ophthalmology Announces Distribution Agreement With AFT Pharmaceuticals
Brief: Zhaoke Ophthalmology Says NMPA Acceptance Of New Drug Application For NVK002
Brief: Zhaoke Ophthalmology Says NMPA Granted Marketing Authorizations For Three Drugs
Brief: Zhaoke Ophthalmology Says Marketing Authorization For Bimatoprost Eye Drop Obtained
Brief: Zhaoke Ophthalmology Posts HY Loss RMB75.8 Million
Brief: Zhaoke Ophthalmology Posts H1 Revenue RMB49.8 Million
Brief: Zhaoke Ophthalmology Sees Loss Of No More Than RMB77 Million For Six Months
Brief: Zhaoke Ophthalmology Says Approval Of Investigational New Drug Application By NMPA
Brief: Zhaoke Ophthalmology Posts FY Revenue Rmb18.8 Million
Brief: Zhaoke Ophthalmology Enters Distribution Agreement With Kwangdong Pharmaceutical
Brief: GIC Private Ltd's Long Position In Zhaoke Ophthalmology Falls To 9.99% - HKEX Filing
Brief: Zhaoke Ophthalmology Says Clinical Trial Met Primary Efficacy Endpoint
Brief: GIC Private Ltd's Long Position In Ordinary Shares Of Zhaoke Ophthalmology Falls To 10.65% - Filing
Brief: Zhaoke Ophthalmology Ltd Says HY Revenue Rmb11.3 Mln
Brief: GIC Private Ltd's Long Position In Hong Kong Shares Of Zhaoke Ophthalmolog Falls To 11.99% - Filing
Brief: Zhaoke Ophthalmology Enters Exclusive Agreements With Eyedetec Medical To Commercialize Eye Lipid Mobilizer
China's Zhaoke jumps as US FDA accepts new drug application for myopia treatment